본문 바로가기

Alitretinoin can be a good treatment option for idiopathic recalcitrant trachyonychia in adults: an open-label study

문서 유형
연구출판물 · 학술지 논문
등재
SCIEScopus
저널 순위
JCR Q1Scopus Q1
피인용
Web of Science 5Scopus 7
FWCI (Scopus)
0.36
JCR IF
JCR 2017 4.287
ISSN
0926-9959

저자

  1. 신기혁제1저자Department of Dermatology, School of Medicine, Pusan National University, Busan, South Korea
  2. 김태욱Department of Dermatology, School of Medicine, Pusan National University, Busan, South Korea
  3. 박성민Department of Dermatology, School of Medicine, Pusan National University, Busan, South Korea
  4. 이현주Department of Dermatology, School of Medicine, Pusan National University, Busan, South Korea
  5. 진현주Department of Dermatology, School of Medicine, Pusan National University, Busan, South Korea
  6. 류향석Department of Dermatology, School of Medicine, Pusan National University, Busan, South Korea
  7. 심우행Department of Dermatology, School of Medicine, Pusan National University, Busan, South Korea
  8. 김건욱Biomedical Research Institute, Pusan National University Hospital, Busan, South Korea
  9. 김훈수Biomedical Research Institute, Pusan National University Hospital, Busan, South Korea
  10. 고현창Department of Dermatology, School of Medicine, Pusan National University, Busan, South Korea
  11. 김병수Biomedical Research Institute, Pusan National University Hospital, Busan, South Korea
  12. 김문범교신저자Biomedical Research Institute, Pusan National University Hospital, Busan, South Korea

초록

BackgroundTrachyonychia can be refractory to conventional treatments including topical, intralesional or systemic corticosteroids, as well as cyclosporine and retinoids. Therefore, new treatment options are needed for recalcitrant trachyonychia. ObjectiveTo evaluate the efficacy and safety of oral alitretinoin for idiopathic recalcitrant trachyonychia. MethodsA total of 21 adult patients with 210 nails affected by idiopathic recalcitrant trachyonychia were evaluated in this open-label prospective study. All patients took 30 mg of alitretinoin daily for at least 3 months. Clinical outcomes were assessed using the Physician Global Assessment (PGA) scale proposed by Park et al. (degree of roughness: 0, clear; 1, mild; 2, moderate; 3, marked; 4, severe) at baseline and 1, 3 and 6 months after treatment. ResultsAfter 1, 3 and 6 months of treatment, 74.3% (123/210), 98.1% (206/210) and 99.2% (119/120) of nails showed clinical improvement, respectively; 0% (0/210), 22.9% (48/210) and 69.2% (83/120) were completely free from nail abnormalities. The mean PGA score at baseline was 3.4, decreasing significantly to 2.7, 1.3 and 0.7 at 1, 3 and 6 months following treatment, respectively. LimitationsA small number of participants and lack of a control group were limitations. ConclusionsFor the first time, this study evaluated the efficacy and safety of oral alitretinoin for idiopathic recalcitrant trachyonychia in adults. The results suggest that oral alitretinoin can be a good treatment option for adult patients with recalcitrant trachyonychia.

키워드

CHRONIC HAND ECZEMAOF-THE-LITERATURENAIL LICHEN-PLANUS20-NAIL DYSTROPHYORAL ALITRETINOINEFFICACYCYCLOSPORINESAFETY

식별자

Scopus EID
2-s2.0-85047662761
WoS UID
000446838100051